Entero Therapeutics, Inc. (NASDAQ:ENTO) Sees Significant Increase in Short Interest

Entero Therapeutics, Inc. (NASDAQ:ENTO) was the recipient of a significant growth in short interest in December. As of December 15th, there was short interest totalling 214,800 shares, a growth of 214.5% from the November 30th total of 68,300 shares. Approximately 4.6% of the shares of the stock are short sold. Based on an average trading volume of 461,200 shares, the days-to-cover ratio is presently 0.5 days.

Entero Therapeutics Stock Down 4.6 %

Shares of NASDAQ:ENTO traded down $0.03 on Friday, hitting $0.60. The stock had a trading volume of 100,566 shares, compared to its average volume of 354,361. The firm’s 50 day moving average price is $0.59 and its 200-day moving average price is $0.70. Entero Therapeutics has a twelve month low of $0.19 and a twelve month high of $9.35.

Entero Therapeutics (NASDAQ:ENTO) last announced its earnings results on Monday, October 21st. The company reported ($3.37) earnings per share for the quarter. Equities research analysts predict that Entero Therapeutics will post -1.13 earnings per share for the current fiscal year.

Entero Therapeutics Company Profile

Entero Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of targeted and orally delivered therapies for the treatment of patients with gastrointestinal diseases. The company's pipeline candidates include latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides, currently under Phase 2 studies; and capeserod, a selective 5-HT4 receptor partial agonist under Phase 1 studies for the treatment of gastroparesis.